Siegfried has delivered higher net sales, core EBITDA and core net profit in the first half of 2026, while further expanding its core EBITDA margin, as sustained demand for development and manufacturing services drove growth across multiple markets.

 

The Swiss contract development and manufacturing organization also completed the acquisition of three drug substance sites in the US and Australia on May 1, strengthening its manufacturing footprint and positioning the company for further growth.

 

The integration of the newly acquired sites is progressing as planned, with Siegfried focused on operational alignment and capturing targeted synergies. The company is continuing to execute its EVOLVE+ strategy, centered on Commercial, Development and Operational Excellence, alongside targeted M&A aimed at creating sustainable long-term value.

 

“We increased sales and earnings in the first half, further improved our profitability and completed an important strategic acquisition. The integration of the three new sites is progressing as planned and we are seeing strong customer interest, demonstrating the strategic value of our strengthened US footprint. Based on the solid execution across our business and strong progress in implementing our strategy EVOLVE+, we confirm our outlook,” said Marcel Imwinkelried, Chief Executive Officer.

 

Net sales reached CHF 633 million, up 4.8% in local currencies and 2.2% in Swiss francs compared with the first half of 2025.

 

Drug Substances remained the main growth engine, generating CHF 431.1 million in sales, an increase of 6.4% in local currencies and 4.2% in CHF. Drug Products contributed CHF 201.9 million, up 1.5% in local currencies but down 1.9% in CHF.

 

Siegfried said the seasonal split between the first and second halves of the year is expected to be more pronounced in 2026 than in previous years. The company attributed the shift mainly to the acquisition and the timing of its production plan.

 

Profitability also strengthened. Core EBITDA rose to CHF 142 million from CHF 133.9 million a year earlier, while the core EBITDA margin expanded by 80 basis points to 22.4%.

 

The improvement reflects continued operational gains and a favorable business mix. Core net profit climbed 3.8% to CHF 68.2 million, compared with CHF 65.7 million in the prior-year period.

 

Cash flow from operating activities, however, fell to CHF 93.7 million from CHF 149.6 million a year earlier.

 

The May 1 acquisition added three strategically important assets: a large-scale commercial manufacturing facility in Wilmington, Delaware; an early-phase development and manufacturing site in Athens, Georgia; and the extraction capabilities of Extractas Bioscience in Westbury, Australia.

 

Siegfried plans to use the expanded US footprint to accelerate its exclusive synthesis business, optimizing controlled-substance capacity across its Wilmington facility and nearby Pennsville site.

 

The combination of Wilmington's commercial manufacturing capabilities, Athens' early-phase expertise and Extractas Bioscience's extraction capabilities expands Siegfried's ability to serve customers from early-stage development through commercial manufacturing.

 

Integration is already underway, with the company reporting strong customer interest in the newly added US capacity.

 

The acquired sites are expected to generate around USD 100 million in net sales during 2026. On an annualized basis, the sites are expected to contribute approximately USD 155 million, with an EBITDA margin at or above the Group margin.

 

Siegfried is also progressing with targeted technology upgrades designed to support future growth, as the company continues to implement EVOLVE+ and build capacity around its core development and manufacturing businesses.

 

With first-half sales and profitability ahead of the prior-year period, the strategic acquisition progressing as planned and customer demand remaining strong, Siegfried said it is maintaining its outlook for 2026.